Sanara MedTech (SMTI) Projected to Post Quarterly Earnings on Monday

Sanara MedTech (NASDAQ:SMTI) is expected to be announcing its earnings results before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $22.75 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Sanara MedTech Price Performance

Shares of NASDAQ SMTI opened at $33.60 on Friday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.02 and a current ratio of 2.23. Sanara MedTech has a fifty-two week low of $26.00 and a fifty-two week high of $39.08. The stock has a market cap of $293.70 million, a PE ratio of -33.94 and a beta of 1.37. The stock has a fifty day moving average of $34.36 and a 200-day moving average of $33.84.

Analyst Ratings Changes

A number of research firms have recently commented on SMTI. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Sanara MedTech in a research report on Thursday, January 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $44.00 price target on shares of Sanara MedTech in a report on Wednesday, January 22nd.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.